Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade

Lancet. 1979 Jun 30;1(8131):1374-6. doi: 10.1016/s0140-6736(79)92010-5.

Abstract

24 patients with congestive cardiomyopathy (group I) were compared with a group of 13 controls with similar clinical findings and myocardial function who were selected retrospectively (group II) . All patients received digitalis and diuretics, but group I patients received beta-blockers as well. The survival-rate in group I patients (83%, 66%, and 52% after one, two, and three years respectively) differed significantly from that in group II subjects (46%, 19%, and 10%, respectively). This finding is supported by the demonstration that beta-blockade improved myocardial function in group I subjects. It is therefore suggested that beta-blockade prolongs survival in patients with congestive cardiomyopathy.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Cardiomyopathies / drug therapy*
  • Cardiomyopathies / mortality
  • Clinical Trials as Topic
  • Digitalis Glycosides / administration & dosage
  • Diuretics / administration & dosage
  • Female
  • Follow-Up Studies
  • Heart Failure / drug therapy*
  • Heart Failure / mortality
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Time Factors

Substances

  • Adrenergic beta-Antagonists
  • Digitalis Glycosides
  • Diuretics